AU2020321898B2 - Compositions comprising chemerin analogs and methods of use - Google Patents

Compositions comprising chemerin analogs and methods of use

Info

Publication number
AU2020321898B2
AU2020321898B2 AU2020321898A AU2020321898A AU2020321898B2 AU 2020321898 B2 AU2020321898 B2 AU 2020321898B2 AU 2020321898 A AU2020321898 A AU 2020321898A AU 2020321898 A AU2020321898 A AU 2020321898A AU 2020321898 B2 AU2020321898 B2 AU 2020321898B2
Authority
AU
Australia
Prior art keywords
composition
acid
pain
peptide
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020321898A
Other languages
English (en)
Other versions
AU2020321898A1 (en
Inventor
Rajkumar V. Patil
Kunwar Shailubhai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OKYO Pharma Ltd
Original Assignee
OKYO Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OKYO Pharma Ltd filed Critical OKYO Pharma Ltd
Publication of AU2020321898A1 publication Critical patent/AU2020321898A1/en
Application granted granted Critical
Publication of AU2020321898B2 publication Critical patent/AU2020321898B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2020321898A 2019-08-01 2020-07-29 Compositions comprising chemerin analogs and methods of use Active AU2020321898B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962881725P 2019-08-01 2019-08-01
US62/881,725 2019-08-01
PCT/US2020/044045 WO2021021915A1 (en) 2019-08-01 2020-07-29 Compositions comprising chemerin analogs and methods of use

Publications (2)

Publication Number Publication Date
AU2020321898A1 AU2020321898A1 (en) 2022-03-03
AU2020321898B2 true AU2020321898B2 (en) 2026-02-19

Family

ID=72087242

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020321898A Active AU2020321898B2 (en) 2019-08-01 2020-07-29 Compositions comprising chemerin analogs and methods of use

Country Status (6)

Country Link
US (1) US12559523B2 (enExample)
EP (2) EP4007635B1 (enExample)
JP (1) JP7651553B2 (enExample)
AU (1) AU2020321898B2 (enExample)
CA (1) CA3149397A1 (enExample)
WO (1) WO2021021915A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023220676A2 (en) * 2022-05-12 2023-11-16 Okyo Pharma Limited Formulation for treating dry eye disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014168721A2 (en) * 2013-04-12 2014-10-16 Tufts Medical Center Methods and systems for designing and/or characterizing soluble lipidated ligand agents
WO2017127827A1 (en) * 2016-01-22 2017-07-27 Tufts Medical Center Compounds and methods for treating inflammation
WO2019001459A1 (zh) * 2017-06-27 2019-01-03 凯惠科技发展(上海)有限公司 一种肽类化合物、其应用及含其的组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7419658B2 (en) * 2001-07-09 2008-09-02 Euroscreen S.A. Isolated ligand of ChemerinR
US20090053831A1 (en) * 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
JP2010229093A (ja) * 2009-03-27 2010-10-14 Banyu Pharmaceut Co Ltd 新規ＣｈｅｍｅｒｉｎＲアゴニスト
US20170039314A1 (en) * 2010-03-23 2017-02-09 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2013117581A1 (en) 2012-02-10 2013-08-15 Charite - Universitätsmedizin Berlin Metabolically stable variants of chemerin 9

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014168721A2 (en) * 2013-04-12 2014-10-16 Tufts Medical Center Methods and systems for designing and/or characterizing soluble lipidated ligand agents
WO2017127827A1 (en) * 2016-01-22 2017-07-27 Tufts Medical Center Compounds and methods for treating inflammation
WO2019001459A1 (zh) * 2017-06-27 2019-01-03 凯惠科技发展(上海)有限公司 一种肽类化合物、其应用及含其的组合物

Also Published As

Publication number Publication date
CA3149397A1 (en) 2021-02-04
US12559523B2 (en) 2026-02-24
EP4218927A3 (en) 2023-08-09
WO2021021915A1 (en) 2021-02-04
AU2020321898A1 (en) 2022-03-03
EP4007635B1 (en) 2024-06-19
EP4007635A1 (en) 2022-06-08
JP7651553B2 (ja) 2025-03-26
JP2022543598A (ja) 2022-10-13
EP4218927A2 (en) 2023-08-02
US20220267377A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
US12053501B2 (en) Methods for treating symptoms of dry eye disease
JP6364352B2 (ja) 部分的ｍｈｃコンストラクト及びその使用方法
EP3599245A1 (en) Il-17a binding polypeptides and medical uses thereof
WO2018039147A1 (en) THERAPEUTIC USES OF LAG3 THE α-SYNUCLEIN TRANSMISSION RECEPTOR
EP4007635B1 (en) Compositions comprising chemerin analogs and methods of use
JP2025516630A (ja) ドライアイ疾患治療用製剤
WO2018195491A1 (en) Compositions and methods for the treatment of amyotrophic lateral sclerosis
EP4007636B1 (en) Compositions comprising bovine adrenal medulla 8-22 (bam8-22) peptide analogs and methods of use
US12171858B2 (en) Peptide for treating sepsis derived from Rv2626c protein of Mycobacterium tuberculosis
HK40097419A (en) Compositions comprising chemerin analogs and methods of use
HK40075089A (en) Compositions comprising chemerin analogs and methods of use
HK40075089B (en) Compositions comprising chemerin analogs and methods of use
US20230203107A1 (en) Peptide for treating sepsis derived from rv3364c protein of mycobacterium tuberculosis
HK40000831A (en) Compounds and methods for treating inflammation
HK40000831B (en) Compounds and methods for treating inflammation
WO2022183360A1 (en) Short synthetic peptide and their uses for treating dry eye disease

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)